UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000033594 |
|---|---|
| Receipt number | R000037875 |
| Scientific Title | Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancer |
| Date of disclosure of the study information | 2018/08/01 |
| Last modified on | 2018/08/01 18:45:23 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancer
Acronym
Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancer
Scientific Title
Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancer
Scientific Title:Acronym
Investigation of post-treatment after immune checkpoint inhibitor treatment for advanced or recurrent non-small cell lung cancer
Region
| Japan |
Condition
Condition
lung cancer
Classification by specialty
| Pneumology | Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Investigation of the characteristics of clinical, image, therapeutic agents, etc. for cases after treatment with immune checkpoint inhibitors for advanced or recurrent non-small cell lung cancer
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Response rate
Key secondary outcomes
Progression-free survival
Overall survival
Side effect
Types of immunity checkpoint inhibitors
Types of anti-cancer drugs
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Advanced or recurrent non-small cell lung cancer in which an immune check point inhibitor was used at our center
Key exclusion criteria
Patient, or family refuses to participate in the study
Target sample size
37
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Takehiro Izumo |
Organization
Japanese Red Cross Medical Center
Division name
Respiratory Medicine
Zip code
Address
4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan
TEL
03-3400-1311
drtake1118@gmail.com
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Mari Tone |
Organization
Japanese Red Cross Medical Center
Division name
Respiratory Medicine
Zip code
Address
4-1-22, Hiroo, Shibuya-ku, Tokyo, Japan
TEL
03-3400-1311
Homepage URL
m.tone.0829@gmail.com
Sponsor or person
Institute
Japanese Red Cross Medical Center
Institute
Department
Personal name
Funding Source
Organization
Japanese Red Cross Medical Center
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 08 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2016 | Year | 01 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2016 | Year | 01 | Month | 01 | Day |
Last follow-up date
| 2018 | Year | 04 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
| 2018 | Year | 09 | Month | 30 | Day |
Other
Other related information
Single facility observational study
Management information
Registered date
| 2018 | Year | 08 | Month | 01 | Day |
Last modified on
| 2018 | Year | 08 | Month | 01 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037875
